Michellr's answer was that there's no time for EMD...

First 359 Last

Share
Profile

Follow
IndexInvestor

8,391 Posts.

1383

13/08/23

17:38

Post #: 69313075
Share

Originally posted by Davisite: ↑

The problem appears to be more or less universal given the current thinking in the AML haematology community around EMD AML. There is a recognition that EMD is an important issue (hence why the strong clinician interest in being part of trials), but since there are no specific treatments for EMD AML it is not seen as important to know if an individual r/r AML patient has EMD or not. Of course unless EMD is diagnosed first you can't develop treatments is one of those chicken-and-the-egg type problems all too common in medicine.

A similar thing happened with clinician thinking around minimal residual disease (MRD) in AML. It has been known for almost two decades in other leukemias that MRD status is very important for disease outcome post stem cell transplant, but due to technical issues diagnosing MRD in AML it was not considered by most clinicians for AML patients. This all changed about 3 years ago when various breakthroughs in flow cytometry and DNA sequencing allowed MRD status to be routinely determined in AML patients and this has revolutionised the treatment of AML. Getting a patient to MRD(-) before transplant is now the goal for AML patients able to tolerate a stem cell transplant.

The solution to the EMD trial problem is to remove the requirement for prescreening in the EMD AML trial and allow any patient the doctor suspects has EMD to enrol for treatment with bisantrene. Once on the trial the patient could then be checked for EMD without delaying treatment. I did ask Michelle on Friday why this was not the plan for the proposed new RAC-009 AML trial, but I didn't understand her answer. Maybe someone who was there could comment.

Expand

Michellr's answer was that there's no time for EMD screening before the patient needs to be treated. Which doesn't answer your question.

RAC Price at posting: $1.00 Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

PL3

Patagonia looks to raise $2.15M for South American exploration and development

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

There are more pages in this discussion • 234 more messages in this thread...

First 359 Last

Add RAC (ASX) to my watchlist

(20min delay)
Last $1.75		Change 0.010(0.57%)		Mkt cap ! $298.0M

Open	High	Low	Value	Volume
$1.73	$1.83	$1.73	$272.0K	152.3K

Buyers (Bids)

No.	Vol.	Price($)
1	9998	$1.75

Sellers (Offers)

Price($)	Vol.	No.
$1.79	2000	1

View Market Depth

No.	Vol.	Price($)
1	9998	1.750
1	7599	1.730
1	581	1.720
3	11557	1.710
4	46280	1.700

Price($)	Vol.	No.
1.790	2000	1
1.830	44030	2
1.840	10500	2
1.850	14500	3
1.860	949	2

Last trade - 16.10pm 09/07/2024 (20 minute delay)

RAC (ASX) Chart

Michellr's answer was that there's no time for EMD...

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Patagonia looks to raise $2.15M for South American exploration and development

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Michellr&apos;s answer was that there&apos;s no time for EMD...

Top Stories

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Patagonia looks to raise $2.15M for South American exploration and development

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Michellr's answer was that there's no time for EMD...